Quest Diagnostics (DGX) Competitors $179.07 -1.89 (-1.04%) Closing price 10/3/2025 03:59 PM EasternExtended Trading$179.33 +0.26 (+0.14%) As of 10/3/2025 06:17 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock DGX vs. HSIC, MEDP, AMN, LH, DVA, CHE, CRVL, MD, CCRN, and EHCShould you be buying Quest Diagnostics stock or one of its competitors? The main competitors of Quest Diagnostics include Henry Schein (HSIC), Medpace (MEDP), AMN Healthcare Services (AMN), Labcorp (LH), DaVita (DVA), Chemed (CHE), CorVel (CRVL), Pediatrix Medical Group (MD), Cross Country Healthcare (CCRN), and Encompass Health (EHC). Quest Diagnostics vs. Its Competitors Henry Schein Medpace AMN Healthcare Services Labcorp DaVita Chemed CorVel Pediatrix Medical Group Cross Country Healthcare Encompass Health Henry Schein (NASDAQ:HSIC) and Quest Diagnostics (NYSE:DGX) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, risk, profitability, media sentiment, valuation, dividends, institutional ownership and analyst recommendations. Which has better earnings and valuation, HSIC or DGX? Quest Diagnostics has lower revenue, but higher earnings than Henry Schein. Quest Diagnostics is trading at a lower price-to-earnings ratio than Henry Schein, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioHenry Schein$12.67B0.64$390M$3.1021.62Quest Diagnostics$9.87B2.03$871M$8.3521.45 Is HSIC or DGX more profitable? Quest Diagnostics has a net margin of 9.01% compared to Henry Schein's net margin of 3.05%. Quest Diagnostics' return on equity of 15.24% beat Henry Schein's return on equity.Company Net Margins Return on Equity Return on Assets Henry Schein3.05% 14.36% 5.52% Quest Diagnostics 9.01%15.24%6.64% Do institutionals & insiders hold more shares of HSIC or DGX? 96.6% of Henry Schein shares are owned by institutional investors. Comparatively, 88.1% of Quest Diagnostics shares are owned by institutional investors. 1.1% of Henry Schein shares are owned by insiders. Comparatively, 8.2% of Quest Diagnostics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Which has more risk & volatility, HSIC or DGX? Henry Schein has a beta of 0.81, suggesting that its stock price is 19% less volatile than the S&P 500. Comparatively, Quest Diagnostics has a beta of 0.56, suggesting that its stock price is 44% less volatile than the S&P 500. Does the media prefer HSIC or DGX? In the previous week, Quest Diagnostics had 17 more articles in the media than Henry Schein. MarketBeat recorded 20 mentions for Quest Diagnostics and 3 mentions for Henry Schein. Quest Diagnostics' average media sentiment score of 1.10 beat Henry Schein's score of -0.16 indicating that Quest Diagnostics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Henry Schein 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Quest Diagnostics 13 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts prefer HSIC or DGX? Henry Schein currently has a consensus price target of $76.67, suggesting a potential upside of 14.38%. Quest Diagnostics has a consensus price target of $186.31, suggesting a potential upside of 4.04%. Given Henry Schein's higher probable upside, research analysts plainly believe Henry Schein is more favorable than Quest Diagnostics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Henry Schein 0 Sell rating(s) 8 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.38Quest Diagnostics 0 Sell rating(s) 10 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 2.53 SummaryQuest Diagnostics beats Henry Schein on 12 of the 17 factors compared between the two stocks. Get Quest Diagnostics News Delivered to You Automatically Sign up to receive the latest news and ratings for DGX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding DGX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart DGX vs. The Competition Export to ExcelMetricQuest DiagnosticsMED IndustryMedical SectorNYSE ExchangeMarket Cap$20.05B$4.22B$6.13B$21.82BDividend Yield1.78%1.26%5.66%3.54%P/E Ratio21.4526.9386.8829.81Price / Sales2.03233.54605.4267.73Price / Cash13.2828.4726.3018.31Price / Book2.924.7112.534.65Net Income$871M$197.51M$3.30B$1.00B7 Day Performance-5.35%0.91%4.28%2.07%1 Month Performance-2.38%2.85%6.90%3.33%1 Year Performance18.76%26.34%70.54%13.11% Quest Diagnostics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)DGXQuest Diagnostics4.7925 of 5 stars$179.07-1.0%$186.31+4.0%+18.8%$20.05B$9.87B21.4556,000Positive NewsAnalyst ForecastHSICHenry Schein3.8009 of 5 stars$66.050.0%$76.67+16.1%-5.0%$8.01B$12.67B21.3125,000Analyst UpgradeMEDPMedpace4.2689 of 5 stars$500.76+0.8%$422.27-15.7%+55.2%$14.07B$2.11B37.235,900News CoveragePositive NewsAMNAMN Healthcare Services4.1348 of 5 stars$18.51-1.9%$23.25+25.6%-46.6%$709.38M$2.98B-2.382,968LHLabcorp4.8193 of 5 stars$282.65+0.7%$290.33+2.7%+28.0%$23.49B$13.01B31.2070,000News CoverageAnalyst ForecastDVADaVita4.7589 of 5 stars$130.66-0.1%$158.00+20.9%-18.4%$9.34B$12.82B12.8576,000Positive NewsCHEChemed5 of 5 stars$452.36-2.1%$578.50+27.9%-23.9%$6.59B$2.43B23.2615,695Positive NewsCRVLCorVel1.2647 of 5 stars$77.22-1.8%N/A-30.0%$3.96B$895.59M39.805,075Analyst DowngradeMDPediatrix Medical Group1.7305 of 5 stars$16.21-0.5%$16.79+3.5%+44.4%$1.41B$2.01B12.574,305News CoverageAnalyst UpgradeCCRNCross Country Healthcare3.3568 of 5 stars$13.76-3.3%$17.93+30.3%+7.6%$450.78M$1.34B-52.928,205EHCEncompass Health4.8826 of 5 stars$125.83-0.7%$138.43+10.0%+30.3%$12.67B$5.37B24.6240,000News CoverageAnalyst Forecast Related Companies and Tools Related Companies Henry Schein Alternatives Medpace Alternatives AMN Healthcare Services Alternatives Labcorp Alternatives DaVita Alternatives Chemed Alternatives CorVel Alternatives Pediatrix Medical Group Alternatives Cross Country Healthcare Alternatives Encompass Health Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:DGX) was last updated on 10/5/2025 by MarketBeat.com Staff From Our PartnersMagnificent 7 being replaced by the “Hidden 7”?BULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredU.S. Government Sparking Crypto RallyU.S. Puts GDP on the Blockchain Could this spark the next crypto supercycle? Discover the altcoins poised t...Crypto 101 Media | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredRIP USA"The America you knew is dying in front of you" That's the urgent warning the former $200 million hedge fun...Stansberry Research | Sponsored2013 miner reveals his trading systemWhile everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Quest Diagnostics Incorporated Please log in to your account or sign up in order to add this asset to your watchlist. Share Quest Diagnostics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
